Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386346 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL7423417 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL2313063 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13163967 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29361981 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29511158 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL8350965 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13636676 | 0.91 | MDM4 (0.51) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL18358965 | 0.91 | CASP3 (0.55) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29477062 | 0.90 | MDM4 (0.55) | CASP3MDM4TP53MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705299-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | Rayzebio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4516321-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024229154-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| CN-117024476-A | diphenylphosphonooxy-X-phenol compound, preparation method and application in preparation of aspartame | 西北工业大学 | 2023-11-10 | — | — | CN | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | CASP3 1664/4885MDM4 3536/4885TP53 238/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885MDM4 3559/4885TP53 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.